Product Description
Adenosine A1 Antagonist for Asthma and COPD (Sourced from: https://www.palobiofarma.com/pipeline-2/)
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Palobiofarma SL
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Asthma|Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05262218 |
Respire | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-02-27 |
33% |
2024-04-20 |
Primary Completion Date|Primary Endpoints |
2017-003663-35 |
2017-003663-35 | P2 |
Active, not recruiting |
Asthma |
2019-02-14 |
2022-03-13 |
Treatments |
|
2021-001732-25 |
2021-001732-25 | P2 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2023-01-07 |
2025-06-30 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/26/2019 |
News Article |
XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets |